Vascular endothelial growth factor (VEGF) is a secreted mitogen associated with angiogenesis. VEGF has long been thought to be a potent neurotrophic factor for the survival of spinal cord neurons. However, the role of VEGF in the regulation of ischemic brain injury remains unclear. In this study, rats were subjected to MCAO (middle cerebral artery occlusion) followed by intraperitoneal injection of VEGF165 (10 mg/kg) immediately after surgery and once daily until the day 10. The expression of target genes was assayed using qPCR, western blot and immunofluorescence to investigate the role of VEGF165 in regulating ischemic brain injury. We found that VEGF165 significantly inhibited MCAO-induced upregulation of Scavenger receptor class A (SR-A) on microglia in a VEGFR1-dependent manner. VEGF165 inhibited lipopolysaccharide (LPS)-induced expression of proinflammatory cytokines IL-1b, tumor necrosis factor alpha (TNF-a) and iNOS in microglia. More importantly, the role of VEGF165 in inhibiting neuroinflammation is partially abolished by SR-A over-expression. SR-A further reduced the protective effect of VEGF165 in ischemic brain injury. These data suggest that VEGF165 suppresses neuroinflammation and ischemic brain injury by inhibiting SR-A expression, thus offering a new target for prevention of ischemic brain injury.
Ischemic brain injury often leads to persisting functional deficits in the affected patients and is one of the leading causes of death worldwide (Kidwell et al. 2001; Shi et al. 2011) . Cerebral ischemia is a complex pathological process that can cause irreversible brain injury, and involves multiple mechanisms such as free-radical generation (Moro et al. 2005) , oxidative stress (Akpinar et al. 2016) , neuronal apoptosis and neuroinflammation mediated by activated microglia (Kim et al. 2007) . Neuroinflammation has been shown to play an important role in different brain diseases such as Parkinson's disease (Tansey and Goldberg 2010 ), Alzheimer's disease (Eikelenboom et al. 2002) and cerebral ischemic stroke (del Zoppo et al. 2000; Iadecola and Alexander 2001) . Emerging studies showed that inhibition of inflammatory response contributes to decrease infarct size and neurological deficit following ischemia injury (Villa et al. 2003) . Currently, the suitable therapy for inhibiting inflammatory injury following cerebral ischemia has been limited because the pathological mechanisms causing neuroinflammation remain unclear. Revealing the underlying mechanisms for the development of neuroinflammation is indispensable for developing effective therapeutic interventions for the treatment of ischemic brain injury.
Vascular endothelial growth factor (VEGF) is a secreted mitogen associated with angiogenesis and revascularization (Ferrara and Davis-Smyth 1997; Hicklin and Ellis 2005) . Earlier studies showed that angiogenesis and vascular remodeling play a pivotal role in the pathophysiology of chronic inflammatory diseases and may be essential for the persistence of the condition (Doige and Furneaux 1975; Guo et al. 2016) . Protection by VEGF has also been demonstrated in MCAO models of stroke (Greenberg and Jin 2013) . Topical application of VEGF to the cortical surface in rat brain reduces ischemic damage after transient ischemia (Hayashi et al. 1998) . On the contrary, intraventricular infusion of an anti-VEGF antibody increases infarct volume after focal cerebral ischemia in rats (Bao et al. 1999) . These results, together with other studies, suggest that VEGF is neuroprotective against ischemic brain injury.
Scavenger receptor A (SR-A, also known as the macrophage scavenger receptor) plays regulatory roles in lipid metabolism, atherogenesis and other metabolic processes (Kelley et al. 2014) . Emerging studies reveal the roles of SR-A in the regulation of innate immunity, inflammatory response, sepsis and ischemic injury (Kelley et al. 2014) . Xu et al. (2012) reported that SR-A expression is up-regulated in brain tissue after MCAO. SR-A À/À mice subjected to MCAO show a less brain damage compared with WT mice. SR-A knockout results in a decrease in microglia/macrophage M1 activation with preservation of M2 markers (Xu et al. 2012) . The role of SR-A in cerebral ischemia/reperfusion injury was also assayed. Lu et al. (2010) demonstrated that deletion of SR-A results in a less cerebral damage (smaller infarct size) after ischemia and suppresses cerebral and systemic inflammatory response when compared with WT mice with cerebral ischemia/ reperfusion.
Based on above findings, we tested the hypothesis that VEGF is neuroprotective against ischemic brain injury by regulating SR-A expression. We demonstrated that VEGF165 inhibits MCAO-induced up-regulation of SR-A on microglia in vivo and in vitro. VEGF165 contributes to inhibit LPS-induced expression of proinflammatory cytokines by regulating SR-A. VEGF165 treatment also reduces infarct volume after ischemic brain injury by the mediation of SR-A.
Materials and methods

Reagents
The recombinant VEGF165 was purchased from Biovision (Milipitas, CA, USA). VEGF is a double, non-glycosylated, polypeptide containing 164 amino acids and having a molecular mass of 38.4 kDa. The antibodies used in the study include SR-A (sc-20444; Santa Cruz Biotechnology, CA, USA, RRID: AB_2148524), Iba1 (ab15690; Abcam, Cambridge, CA, USA, RRID: AB_2224403), GFAP (ab7260; Abcam, RRID: AB_305808), NeuN (ab177487; Abcam, RRID: AB_2532109) and b-actin (A5114; Sigma, St. Louis, MO, USA, RRID: AB_2335679). Enzyme-linked immunosorbent assay (ELISA) kits for IL-1b, TNF-a and iNOS were obtained from R&D Systems (Minneapolis, MN, USA). Recombinant adenovirus containing SR-A (AdSR-A) was obtained from GenePharma (Shanghai, China). The SR-A-specific siRNAs (sc-40188) were obtained from Santa Cruz Biotechnology. The VEGF165-specific siRNA (sense strand sequence: 5 0 -AUGUGAAUGCAGACCAAAGAATT-3 0 ) was synthesized from GenePharma as previously described (Castro-Rivera et al. 2004) . LPS was purchased from Sigma. Trizol reagent, the M-MLV Reverse Transcriptase kit and Oligo(dT)18 primer were purchased from Invitrogen (Carlsbad, CA, USA). All other chemicals were from Sigma unless indicated otherwise.
Drug administration
The experimental protocol was approved by the Institutional Animal Care and Use Committee of the Second Military Medical University. Adult male Sprague-Dawley rats (weight, 280 AE 10 g) were purchased from the Chinese Academy of Sciences (Shanghai, China), and maintained in a pathogen-free facility with a constant humidity and temperature at 12 h/12 h light/dark cycle with free access to food and water. The rats were randomly assigned into three groups (seven rats/group): Sham group, MCAO group and VEGF group (VEGF treatment after MCAO). Rats in VEGF group were given an intraperitoneal injection of VEGF165 (10 mg/kg) immediately after surgery and once daily until the day 10. Researchers (Kaiwei Han and Jigang Chen) blinded to the group assignment performed neurobehavioral tests, infarct volume assessment and cell counting.
Animal models of ischemia stroke
The animals were subjected to permanent middle cerebral artery occlusion (pMCAO) as previously described (Shi et al. 2011; Zhou et al. 2011) . Briefly, before the operation to induce MCAO, animals were anesthetized with intraperitoneal injection of 5% choral hydrate (350 mg/kg). Then, the right common carotid artery, external carotid artery and internal carotid artery were exposed through a midline cervical incision. A piece of 4/0 monofilament nylon suture with its tip slightly rounded by gently heating was inserted through the right internal carotid artery to the base of the middle cerebral artery, thus occluding blood flow to the cortex and striatum. Sham control animals were subjected to similar operations to expose the carotid arteries without occlusion of the middle cerebral artery. The total brains were quickly removed, and the total mRNA and protein were further isolated for qPCR and western blot analysis.
Cell culture and treatment Rat BV2 microglial cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in Dulbecco's modified Eagle's medium (Gibco, Carlsbad, CA, USA) with 10% fetal bovine serum (FBS, Gibco) and 100 lg/mL penicillin-streptomycin (Gibco). Mixed glial cultures were isolated from the cortex of SpragueDawley rats as previously described (Vairano et al. 2001; Zhou et al. 2011) . Primary microglial cultures were obtained from mixed cultures of cortical glial cells. Microglial cells were detached from the astrocytes monolayer by gentle shaking. Primary microglial cells were plated in 96-well plates at a density of 1.5 9 10 5 cells/cm 2 using Dulbecco's modified Eagle's medium-F12 containing 10% FBS and antibiotics. This method acquired~98% Iba1-positive microglial cells (Vairano et al. 2001; Zhou et al. 2011) . Microglial cells were treated with VEGF165 (80 ng/mL), siVEGF (50 nM), AdSR-A (multiplicity of infection = 5), LPS (0.5 ng/lL), siSR-A (50 nM), and then the total mRNA and protein was isolated for qPCR and western blot analysis.
RNA extraction and quantitative real-time PCR (qPCR)
Total RNA was extracted from brain tissues or microglial cells using Trizol reagent according to the manufacturer's instruction. The reverse-transcription reactions were performed using a M-MLV Reverse Transcriptase kit and Oligo(dT)18 primer. qPCR was carried out using a standard SYBR Green PCR kit (Toyobo, Osaka, Japan) protocol on the Applied Biosystems 7300 Real Time PCR system (Applied Biosystems, Foster City, CA, USA). b-Actin was used as an internal control. Primer sequences of qPCR as follows: SR-A, forward primer (AGATGACAGAGAATCAGAGGC), reverse primer (AACACAAGGAGGTAGAGAGCA); TNF-a, forward primer (GCCCTGGTATGAGCCCATG),reverse primer (CGGACTCCGTGATGTCTAAG); iNOS, forward primer (CAG CACAGAGGGCTCAAAG), reverse primer(GCACCCAAACA CCAAGG); IL-1b, forward primer (GAAACAGCAATGGTCGGG), reverse primer (GACACGGGTTCCATGGTG).
Immunoprecipitation
Cells were lysed in kinase lysis buffer (New England Biolabs, MA, USA) and lysates were incubated with anti-VEGFR1 antibodies (13687-1-AP, 1 : 500; Proteintech, Rosemont, IL, USA). Immunoprecipitation was carried out as previously described (Lee et al. 2007 ).
Western blot analysis
After quantification of the protein samples using a Micro BCA TM Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA), equivalent amounts of total protein (60 lg) were electrophoresed through a 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel, and then electrotransferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories, Hercules, CA, USA). The blots were incubated overnight at 4°C with the indicated antibodies (SR-A, sc-20444, 1 : 500, Santa Cruz; VEGFR1 pTyr1213, AP55933PU-N, 1 : 800, OriGene, Rockville, MD, USA; VEGFR1, 13687-1-AP, 1 : 1000; Proteintech), and then incubated with a goat anti-rabbit/ mouseHRP-conjugated secondary antibody (1 : 5000; Santa Cruz Biotechnology). Protein signals were visualized using a chemiluminescence substrate (Thermo Scientific, Sunnyvale, CA, USA). The intensity of the selected bands was quantified using Image J software (National Institutes of Health, Bethesda, MD, USA).
Immunofluorescence Mouse brain tissues embedded in paraffin were sectioned into 3 lm thick slices. The slices were then deparaffinized in xylene and antigen was retrieved by a microwave. The slices were incubated with indicated primary antibodies (SR-A, sc-20444, 1 : 200; Iba1, ab15690, 1 : 100; NeuN, ab177487, 1 : 500; GFAP, ab7260, 1 : 500) after blocking in 5% normal goat serum and permeabilizing in 0.5% Triton X-100 in phosphate-buffered saline (PBS). The slices were rinsed thrice in PBS and then incubated with FITC-conjugated goat anti-goat IgG (20 lg/mL; Boster Biological Technology, CA, USA) or Cy3-conjugated goat anti-rabbit IgG (20 lg/mL; Boster Biological Technology) for 1 h. Fluorescence was observed using a FluoView TM FV1000 confocal microscope (Olympus, Tokyo, Japan).
ELISA IL-1b, TNF-a and iNOS levels in microglial cells were assayed after stimulation with LPS (0.5 ng/lL) or VEGF plus SR-A as previously Rats were subjected to MCAO followed by treatment with VEGF165 and then the mRNA level of SR-A was assayed by qPCR (n = 7. n, number of rats, similarly hereinafter). Total RNA was extracted from total brains and was subjected to qPCR to analyze the expression level of SR-A in each sample. b-Actin was used as an internal control. The 2 ÀDDCt method was used to determine the relative quantization of gene expression levels. *p < 0.05 versus Sham, # p < 0.05 versus MCAO.
(b) Rats were subjected to MCAO followed by treatment with VEGF165 and the protein level of SR-A was assayed using western blot analysis (n = 7). *p < 0.05 versus Sham, # p < 0.05 versus MCAO.
described (Shi et al. 2011) . Plates were read using a Spectra MAX 190 microplate reader (Molecular Devices, Sunnyvale, CA, USA) at a 450 nm wavelength.
Cerebral infarct assessment
Rats were perfused with heparinized PBS (0.05 M) followed by icecold 15% sucrose in PBS, and brains were excised, sectioned and stained with 2% 2,3,5-triphenyltetrazolium chloride (Amresco, Solon, Oh, USA) for 10 min at 37°C. The 2,3,5-triphenyltetrazolium chloride-negative areas which appeared pale were defined as infarct regions, while the normal regions appeared red. Infarct volume was measured in each slice and summed using computerized planimetry (PC-based image tools software).
Neurologic severity scores Neurologic deficits of rats were carried out at 1, 4, 7, 10 and 14 days after MCAO by the modified neurological severity scores (mNSS) as previously described (Chen et al. 2001; Li et al. 2016) . The mNSS composes tests of motor function, gait, balance and reflex, and is widely used to assess the neurological function of MCAO mice. The neurologic function was graded 0-14 scores (0, no neurologic deficit; 14, maximal deficit). The assessment was conducted in triplicate and performed by investigators who blinded to the treatment and groups.
Oxygen and glucose deprivation model Primary microglial cells were exposed to the oxygen and glucose deprivation procedure according to the method described previously (Domin et al. 2016 ).
Statistical analysis
In order to obtain 80% power in our in vivo studies, we conducted a power analysis using our historical data to detect a statistically significant difference of 20% in one single functional test and determined to use 6-8 mice per group when feasible. All data are expressed as mean AE standard deviation (SD) from at least three separate experiments. Averaged data were compared using unpaired Student's t-test, non-parametric test or one-way ANOVA, followed by the Scheff e test. A p-value of less than 0.05 was deemed statistically significant. 
Results
VEGF165 inhibits MCAO-induced expression of SR-A
To investigate the underlying mechanism of VEGF in the regulation of ischemic brain injury, we re-analyzed a recently published microarray dataset (GSE58720) to identify the differentially expressed genes associated with VEGF in MCAO rats. Bioinformatic analysis reveals that SR-A (macrophage scavenger receptor 1) is up-regulated following MCAO, whereas VEGF treatment inhibits MCAO-induced up-regulation of SR-A ( Figure S1 and Table S1 ). Here, we further investigated the role of SR-A in ischemic brain injury because SR-A plays important roles in regulating cerebral inflammatory responses (Xu et al. 2012) . The differential expression of SR-A from microarray experiments was validated using qPCR in the study. Rats were subjected to MCAO followed by treatment with VEGF165. As shown in Fig. 1 (a), SR-A mRNA level is markedly increased after MCAO, whereas VEGF165 treatment significantly decreases the MCAO-induced up-regulation of SR-A in rats by about 50%. The protein level of SR-A was further assayed in rats of sham operation, MCAO alone and VEGF-treating groups. Figure 1(b) showed that the protein expression of SR-A is up-regulated after MCAO, whereas VEGF165 treatment markedly inhibits MCAOinduced protein expression of SR-A.
VEGF165 inhibits SR-A expression on microglia in a VEGFR1-dependent manner
Previous studies showed that SR-A is preferentially expressed on macrophages (Kelley et al. 2014) . As the resident macrophage cells, microglial cells have also been shown to express SR-A (Tichauer and von Bernhardi 2012; Zhang et al. 2014) . Microglia-mediated inflammatory responses play an important role in brain injury in ischemia (Jin et al. 2010; Kuang et al. 2014) . Therefore, we next investigated whether VEGF165 regulates SR-A expression on microglia. To identify in which kind of brain cells SR-A is mainly expressed after MCAO, double immunofluorescence staining was carried out for SR-A and a microglial marker (Iba-1), an astrocytic marker (GFAP) and a neuron marker (NeuN). As shown in Fig. 2(a) , increased accumulation of SR-A is observed in Iba-1-positive cells after MCAO compared with the sham group, whereas VEGF165 treatment inhibits SR-A expression on microglia. GFAP or NeuNpositive cells that also are positive for SR-A can be rarely found in the overlapped images (Fig. 2a) . To further verify whether VEGF165 regulates SR-A expression in microglia, BV2 microglial cells were treated with VEGF165 and the expression of SR-A was assayed. Figure 2(b) and (c) showed that VEGF165 treatment results in a marked decrease in SR-A expression at the mRNA and protein level. On the contrary, knockdown of VEGF165 increases SR-A expression at the mRNA and protein level (Fig. 2d and e) . Furthermore, VEGF165 attenuates the oxygen and glucose deprivation-induced up-regulated of SR-A in cultured primary microglia (Fig. 2f) . There results suggest that VEGF165 inhibits the ischemia-induced up-regulation of SR-A in vitro and in vivo.
VEGF is involved in the essential biology of endothelial cells by acting through its two tyrosine kinase receptors, VEGFR1 and VEGFR2 (Gram et al. 2015; Yamamoto et al. 2016) . Previous studies reported that VEGFR1 is expressed in the brain and up-regulated after brain ischemia (Plate et al. 1999; Hai et al. 2003) . We next investigated whether VEGFR1 mediates VEGF165-induced inhibition of SR-A. Following VEGF165 treatment, total cell extracts were immunoprecipitated with an anti-VEGFR1 antibody followed by immunoblotting with an anti-phosphotyrosine antibody. Figure 3(a) showed that VEGF165 stimulation induces the activation of VEGFR1 in the BV2 cells. We next assayed whether VEGFR1 blockade could abolish the inhibitory effect of VEGF165 on the expression of the SR-A. VEGFR1 neutralizing antibody treatment almost completely abolishes the inhibitory effect of VEGF165 on the expression of SR-A in cultured primary microglia, indicating that the role of VEGF165 is mediated by VEGFR1 (Fig. 3b) . VEGFR1 antibody markedly up-regulates the mRNA and protein expression of SR-A in BV2 cells (Fig. 3c-e) . In an addition, as shown in Fig. 3(f) , VEGFR2 neutralizing antibody does not affect the inhibitory effect of VEGF165 on the expression of SR-A in BV2 cells. These results demonstrate that VEGF165 negatively regulates SR-A expression in a VEGFR1-dependent manner in microglia.
Up-regulated SR-A results in an increased neuroinflammatory response
Recent evidence points to the important roles of SR-A in inflammation and ischemic injury (Kelley et al. 2014) . Here, we demonstrated that the expression of SR-A on microglia is dysregulated after ischemic stroke and microglia-mediated inflammatory responses play an important role in ischemic brain injury (Weinstein et al. 2010) . Therefore, we next investigated whether abnormal expression of SR-A is involved in neuroinflammatory response. SR-A was overexpressed in microglial cells and SR-A-over-expressed microglial cells were stimulated with LPS, and then the proinflammatory cytokines levels were assayed. As shown in Fig. 4(a-c) , forced expression of SR-A significantly increases LPS-induced expression of proinflammatory cytokines IL-1b, TNF-a and iNOS in BV2 cells. Importantly, SR-A knockdown markedly inhibits LPS-induced expression of IL-1b, TNF-a and iNOS in BV2 cells (Fig. 4d-f ). These data suggest that forced expression of SR-A in microglia contributes to the secretion of inflammatory cytokines.
VEGF165 inhibits neuroinflammatory response and ischemic brain injury by regulating SR-A Our data demonstrated that VEGF165 inhibits MCAOinduced expression of SR-A on microglia and SR-A positively regulates neuroinflammation. Thus, we further investigated whether SR-A mediates the role of VEGF165 in inhibiting neuroinflammation and brain injury. BV2 cells were treated with LPS, VEGF165 and SR-A, and then the inflammatory cytokines levels were assayed. Figure 5(a-c) showed that VEGF165 significantly suppresses LPSinduced expression of IL-1b, TNF-a and iNOS, whereas SR-A over-expression partially destroys the role of VEGF165 in inhibiting neuroinflammation. Rats were subjected to MCAO for 24 h followed by treatment with VEGF165 and SR-A, and then brains were collected, and infarct volumes were analyzed. Figure 6 (a) showed that the cerebral infraction volume 24 h after MCAO injury is significantly decreased for MCAO-injury animals treated with VEGF165 compared with vehicle controls. More important, SR-A over-expression partially destroys the role of VEGF165 in inhibiting ischemic brain injury (Fig. 6a) . We also assayed the expression of SR-A at the lesion edge after treatment with VEGF165. As shown in Fig. 6(b) , VEGF165 markedly inhibits the expression of SR-A at the lesion edge. In order to assess the effects of VEGF165 on functional recovery of rats, mNSS tests were performed to assay behavioral outcomes after MCAO. Figure 6(c) showed that the scores of rats in VEGF165-treated group are markedly lower than those in the vehicle group at day 4 after VEGF165 treatment. SR-A partially destroys the role of VEGF165 in functional recovery of rats (Fig. 6c ). These data demonstrate that VEGF165 helps to inhibit ischemiainduced neuroinflammation and subsequent brain injury by regulating SR-A.
Discussion
In the study, the role of VEGF165 in the regulation of ischemic brain injury and its underlying mechanism were investigated in vitro and in vivo. The current data demonstrate that (i) VEGF165 treatment decreases the expression of SR-A in rats with MCAO, (ii) VEGF165 inhibits SR-A expression on microglia in a VEGFR1-dependent manner, (iii) Up-regulated SR-A promotes LPS-induced secretion of IL-1b, TNF-a and iNOS in microglia, (iv) VEGF165 effectively inhibits ischemia-induced neuroinflammation and subsequent brain injury by inhibiting SR-A expression. These results reveal a function of VEGF165 in regulating ischemic brain injury and may provide a novel opportunity to treat the disease. It is increasingly clear that post-ischemic inflammation is an essential step in the progression of brain ischemiareperfusion injury (Shichita et al. 2012) . Microglia are the primary cellular source of increased proinflammatory cytokine levels in the brain (Shichita et al. 2012; Cheng et al. 2014) and are pivotal players in the various processes of brain inflammation (Lakhan et al. 2009 ). Microglia are typically in a quiescent or 'resting' state in the normal adult central nervous system (CNS) but can become activated as non-phagocytic microglia in areas involved in CNS inflammation. Currently, the mechanism of microglia activation is still unclear.
Emerging studies demonstrated the role of SR-A in microglia-mediated inflammatory response (Yang et al. 2015) . Yang et al. (2015) reported that SR-A inhibition increases microglia activation and cytokine production, and sensitizes mice to intracerebral hemorrhage-induced neuron injury. On the contrary, other studies showed that SR-A is a positive regulator of neuroinflammation (Godoy et al. 2012; Xu et al. 2012) . SR-A-deficient mice display a reduced infarct size and improve the neurological function after MCAO compared with wild-type mice controls (Xu et al. 2012) . Mechanistically, SR-A inhibition results in a decrease in inflammatory microglia and attenuates nuclear factorkappaB activation in ischemic brains (Xu et al. 2012) . In the study, we demonstrated that forced expression of SR-A promotes LPS-induced expression of IL-1b, TNF-a and iNOS in BV2 cells, whereas SR-A knockdown markedly inhibits LPS-induced expression of inflammatory cytokines. Our data suggest that SR-A plays an important role in positively regulating neuroinflammation. The expression of SR-A is increased after MCAO, whereas VEGF165 treatment significantly decreases the MCAO-induced up-regulation of SR-A. Increased expression of SR-A is mainly observed in Iba-1-positive cells after MCAO. The GFAP or NeuN-positive cells that also are positive for SR-A can be rarely found after MCAO. Here, we further demonstrated that VEGF165 inhibits SR-A expression on microglia in a VEGFR1-dependent manner. VEGFR1 blockade almost completely abolishes the inhibitory effect of VEGF165 on the expression of the SR-A in microglia. Expectedly, VEGF165 suppresses LPS-induced expression of inflammatory cytokines, whereas SR-A over-expression destroys VEGF165-induced inhibition of neuroinflammation, indicating that SR-A, at least in part, mediates the role of VEGF165 in inhibiting neuroinflammatory response. Furthermore, SR-A partially destroys the role of VEGF165 in inhibiting ischemic brain injury.
VEGF plays an important role in the vascular response to cerebral ischemia because ischemia increases VEGF expression in the brain (Zhang et al. 2002) and VEGF promotes the formation of new cerebral blood vessels (Krum et al. 2002; Sun et al. 2003) . Sun et al. (2003) demonstrated that VEGF improves neurological performance and reduces infarct size after focal cerebral ischemia. VEGF also enhances the delayed survival of newborn neurons in the dentategyrus and subventricular zone, and stimulates angiogenesis in the striatal ischemic penumbra (Sun et al. 2003) . In the study, we further demonstrate that VEGF helps to inhibit ischemiainduced neuroinflammation and subsequent brain injury by regulating SR-A. Although current data confirm that VEGF inhibits SR-A expression on microglia and SR-A partially mediates the effect of VEGF on the regulation of cerebral ischemia injury, underlying mechanism of SR-A dysregulation following VEGF treatment remains unclear.
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